Orphan Drug Designation Granted to SK Bio-Pharmaceuticals’ Carisbamate for the Management of Infantile Spasms
SEOUL, Korea, & FAIR LAWN, N.J.--(BUSINESS WIRE)--SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.